This Guidance document focuses on the antioestrogenic protocol; it is the outcome of the experience gained during the validation test programme and the results obtained thereby with the use of a strong oestrogen receptor antagonist. Due to insufficient validation of this antioestrogenic protocol, this Guidance Document is provided for experimental purpose only. The test will provide supporting evidence in relation to antioestrogenic activity.
Guidance Document on the Uterothrophic Bioassay ‑ Procedure to Test for Antioestrogenicity
Report
Share
Facebook
Twitter
LinkedIn
Abstract
In the same series
-
18 December 2025265 Pages
-
15 December 2025169 Pages
-
Report3 December 2025136 Pages
-
Report3 December 202594 Pages
-
2 June 202540 Pages
-
28 May 202591 Pages
Related publications
-
2 July 2026115 Pages
-
Report2 July 202632 Pages
-
2 July 202615 Pages
-
Report
Assay for the Detection of Glucocorticoid Receptor Agonist and Antagonist Activity of Chemicals
2 July 202634 Pages -
Report
Assays addressing the Adverse Outcome Pathway key event on covalent binding to proteins
2 July 202663 Pages -
Report
Assays addressing the Adverse Outcome Pathway Key Event on Keratinocyte activation
2 July 202698 Pages